Abstract
Fifty-one patients with different connective tissue diseases in either active or clinically inactive phase were studied to detect the incidence of chronic or subclinical consumption coagulopathy in these forms. Every patient received intravenously 20 mu Ci of [125I] fibrinogen and the clearance of the labeled fibrinogen was evaluated and expressed by the T/2 method. The data confirm the activation of the coagulation system in connective tissue diseases. In patients with S.L.E., enhanced fibrinogen consumption was significantly correlated with disease activity, DNA-binding activity test, serum complement level and an aspecific inflammatory index (serum mucoprotein level). These preliminary data suggest the usefulness of complementary treatment in connective tissue diseases to counteract this specific pathogenetic mechanism.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
